Navigation Links
New Drug Duo Helps Fight Colon Cancer
Date:4/15/2008

s called VEGFR2, c-Kit and FLT3. These receptors are also present in normal cells.

The drug appears to work by controlling the growth of blood vessels, which is how this type of liver cancer is able to spread so rapidly.

At 12 weeks, one patient had a partial response and 17 saw their disease stabilize. Progression-free survival lasted an average of four months, and overall survival was 10 months, the researchers report.

"Even though the response rate to make the tumor smaller was observed in only one patient, 50 percent of the patients had stable disease and are doing well," Zhu said. "Sunitinib can be safely given, with close monitoring, to the majority of these patients," he said.

The treatment was well-tolerated, and there were low rates of all blood disorders, the researchers report. Because Sutent has been associated with increased risk of heart problems, all patients taking Sutent -- but especially those who have risks for heart disease -- need careful monitoring and treatment for high blood pressure and other signs of heart problems.

In a third report, researchers from the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia found that blood pressure-lowering drugs called angiotensin receptor blockers appear to retard pancreatic cancer cell growth and cause malignant cells to die.

This type of drug is able to inhibit the function of the hormone angiotensin II in the pancreas. The same receptor is found in pancreatic cancer cells. In laboratory experiments, the researchers found that the drug was able to block the production of a growth factor called VEGF, which helps spur the growth of tumor blood vessels.

"This is really exciting because the role of this receptor has never been known," lead researcher Dr. Hwyda Arafat said in a prepared statement. "It's never been connected to cell division or apoptosis. We're also now further exploring the mechanisms involved. The ex
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
2. Direct Anesthetic Infusion Helps Colorectal Cancer Patients
3. Radiation and drug combo helps boost efficacy of lung cancer treatment
4. Childs Flu Shot Helps Whole Family
5. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
6. Generic prostate drug helps find high-risk cancers early
7. Tamoxifen Helps Treat Bipolar Disorder
8. Imaging Software Helps Track, Treat Injured Brains
9. GPS-like technology helps pinpoint best methods for moving injured players
10. New Website Helps Women Be Fit, Sexy and in Control!
11. Brain Defect Helps Drive Fragile X Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Duo Helps Fight  Colon Cancer
New Drug Duo Helps Fight Colon Cancer
(Date:7/25/2008)...rter financial results -, LAVAL, QC, July 25 /PRN...DAQ: DDSS) today announced that it will host a con... to discuss its second quarter 2008,financial resu... financial,results via news release at approximate...nce call by telephone, dial 416-646-3095 or,1-800-...
(Date:7/25/2008)...erweight or obese is not only a personal issue tha... issue that impacts other people in society. A new...eveals that the extra Medicare cost associated wit...ant financial burden on tax payers, costing up to ...current Medicare population. , The article,s fi...
(Date:7/25/2008)...Fourth Annual Physician On-Call Pay ...swire/ -- Sullivan, Cotter and Associates, Inc.,ha...on-call pay rates and,practices, the 2008 Physicia...th data from 132 healthcare organizations nationwi...ates paid for 33 physician specialty areas along,w...
(Date:7/25/2008)...ire/ -- Sagent Pharmaceuticals, Inc.,a privately-...nced that it,has launched amiodarone HCl injection...e treatment and prophylaxis of frequently recurrin...table ventricular,tachycardia -- a potentially lif...arone HCl injection will be available immediately ...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...e Royal Women's Hospital has found that the most c...nduced labor.// Nearly one-third of the women with... caesarians. The factors enhancing the risk of a C...st-time mothers. "The message we are taking is t...
... the University at Buffalo probing into the effect...fish as a model, have zeroed in on many proteins i...negatively with severe alcohol exposure. The scien... out after prolonged alcohol exposure, after they ...
...inister Anbumani Ramadoss has added a new twist to...angerous even without the added pesticides.// "Al...high-risk factors as much as tobacco and a compreh...ed," he said at the golden jubilee year celebratio...
...e University of South Florida College of Medicine ...in Florida is discouraging medical students// from...cialization. The situation means that many people ...n Deutsch, MD, lead author of the study and chief ...
Other Medicine News:Health News:Brain protein expression can be damaged with prolonged alcohol exposure 2Health News:Malpractice Worry Discouraging Medical Students From Taking Up Obstetrics And Gynecology 2
(Date:7/23/2008)... WASHINGTON, July 23 /PRNewswire-USNewswire/ --... of Justice:, Chairman Conyers, Ranking Member Sm...he opportunity to testify today., Since I appeare...ave,become even better acquainted with the talente...tment and with the work they do, and I have come t...
(Date:7/23/2008)... ASPS Study Finds Some Areas of the Body Have G...IGHTS, Ill., July 23 /PRNewswire-USNewswire/ -- Fa...hrough liposuction was found to be,an excellent so...ations,than other areas of the body, reports a Bra...ructive Surgery(R), the official medical journal o...
(Date:7/23/2008)... SEATTLE, July 23 /- Den... that it expects the Independent Data,Monitoring C...rim analysis,of overall survival relating to the C...e AdenoCarcinoma Treatment, also known as D9902B) ...ENGE is the Company,s investigational,active cellu...
(Date:7/22/2008)... BRISBANE, Australia, July 22 /PRNewswire-First...d late yesterday, the Board of Progen,Pharmaceutic...ed that it,had discontinued the PI-88 phase 3 stud...direction to develop its existing portfolio of com...re additional compounds and,opportunities through ...
Breaking Medicine Technology:Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Looking at neurons from all sides 3069 1Looking at neurons from all sides 3069 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 1deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 3deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 4deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 5Therap Services to Host Conference in Association with the Delaware Division of Developmental Disabilities Services 17817 1Therap Services to Host Conference in Association with the Delaware Division of Developmental Disabilities Services 17817 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 1Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 9
...DNEY, Australia, March 14, 2007 /Xinhua-PRNewswire...day announced the results,from its Phase II trial ...lmonary Disease (COPD), a respiratory disease,affe...l was conducted in 79 diagnosed COPD patients at 1...he trial was to,determine if subjects that were po...
...pany anticipates second quarter BLA filing for C1-... 2007 /PRNewswire-FirstCall/ -- Lev,Pharmaceutical...m,its pivotal U.S. Phase III trial of C1-esterase ...ditary angioedema (HAE). In the,acute study, which...tor in Hereditary Angioedema Nanofiltration Genera...
Other Medicine Technology:Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 2Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 5
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: